计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E302199-1mg |
1mg |
现货 ![]() |
| |
| E302199-5mg |
5mg |
现货 ![]() |
| |
| E302199-25mg |
25mg |
现货 ![]() |
| |
| E302199-100mg |
100mg |
现货 ![]() |
| |
| E302199-500mg |
500mg |
现货 ![]() |
|
| 别名 | 恩曲替尼 |
|---|---|
| 英文别名 | DB11986 | RXDX 101 | ENTRECTINIB [WHO-DD] | RG 6268 | NCGC00484067-01 | NCGC00484067-02 | NSC774769 | NSC-774769 | N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide | 2-hydroxybenzenamine | D1 |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Entrectinib |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | ALK 酪氨酸激酶受体抑制剂 |
| 产品介绍 |
Product Describtion: Entrectinib (RXDX-101, NMS-E628) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Entrectinib (RXDX-101) induces autophagy. |
| 纯度 | ≥98% |
| ALogP | 5.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504769987 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide |
| INCHI | 1S/C31H34F2N6O2/c1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/h2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40) |
| InChi Key | HAYYBYPASCDWEQ-UHFFFAOYSA-N |
| Smiles | CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6 |
| Isomeric SMILES | CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6 |
| 分子量 | 560.64 |
| Reaxy-Rn | 18969663 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=18969663&ln= |
| 分子量 | 560.600 g/mol |
|---|---|
| XLogP3 | 5.700 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 560.271 Da |
| 单同位素质量Monoisotopic Mass | 560.271 Da |
| 拓扑极表面积Topological Polar Surface Area | 85.500 Ų |
| 重原子数Heavy Atom Count | 41 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 846.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L. (2015) Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.. Expert Opin Investig Drugs, 24 (11): (1493-500). [PMID:26457764] |
| 2. Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D et al.. (2015) Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.. J Thorac Oncol, 10 (12): (1670-4). [PMID:26565381] |
| 3. Awad MM, Shaw AT. (2014) ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.. Clin Adv Hematol Oncol, 12 (7): (429-39). [PMID:25322323] |
| 4. Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L. (2015) Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.. Cancer Med, 4 (7): (953-65). [PMID:25727400] |
| 5. Al-Salama ZT, Keam SJ. (2019) Entrectinib: First Global Approval.. Drugs, 79 (13): (1477-1483). [PMID:31372957] |